Oncologie

Phase I/II Study of escalating doses of mitoxantrone in a single injection combined with timed sequential therapy with cytarabine and etoposide in patients with refractory or relapsed acute myeloid leukemia

American Society of Hematology – 41st Annual Meeting – New Orleans, Louisiana – December 3-7, 1999Thomas X, Cambier N, Taksin A-L, Reman O, Vekhoff A, Cordonnier C, Leblond V, Soler-Michel P, Ecstein-Fraïsse E, Archimbaud E.

Vous souhaitez échanger
avec nos équipes

Contactez-nous

D’autres articles qui pourraient
vous intéresser

Use of Digital Health Technology to Enable Drug Development
Oncologie

Use of Digital Health Technology to Enable Drug Development

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study 
Oncologie

Neoadjuvant bevacizumab, trastuzumab, and chemotherapy for primary inflammatory HER2-positive breast cancer (BEVERLY-2): an open-label, single-arm phase 2 study 

Primary efficacy analysis of a phase II study of neoadjuvant Bevacizumab, chemotherapy, and Trastuzumab in HER2-positive inflammatory breast cancer: BEVERLY 2 study
Oncologie

Primary efficacy analysis of a phase II study of neoadjuvant Bevacizumab, chemotherapy, and Trastuzumab in HER2-positive inflammatory breast cancer: BEVERLY 2 study